Elite in IgG4-Related Disease

Nicolas Schleinitz

CHU Caen
Caen, FR 
Elite in IgG4-Related Disease
CHU Caen
Caen, FR 
OverviewLocationsClinical Research

Overview

Nicolas Schleinitz practices in Caen, France. Mr. Schleinitz is rated as an Elite expert by MediFind in the treatment of IgG4-Related Disease. His top areas of expertise are IgG4-Related Disease, Vasculitis, Hypereosinophilic Syndrome, Granulomatosis with Polyangiitis, and Kidney Transplant.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles in the study of IgG4-Related Disease.

Gender
Male

Locations

CHU Caen
Caen, France
Other Locations
CHU Marseille
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drugs: Steroid, Cyclophosphamide, Rituximab
Study Phase: Phase 3
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug
Study Drug: Infliximab
Study Phase: Phase 3
C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis
A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis
Enrollment Status: Withdrawn
Publish Date: January 03, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

166 Total Publications

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schleinitz's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 81 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile